ROS1 and non-small cell lung carcinoma: Crizotinib has also been recommended for funding in Canada for ALK+ NSCLC, and for both ALK+ and ROS1+ NSCLC in other jurisdictions, but has not been found to be cost-effective at the list price in either setting.